Somerset Partnership’s research department held a successful research seminar at The Canalside in Bridgwater last Wednesday.
The seminar, which was attended by more than 80 people from across Somerset Partnership and Taunton and Somerset NHS Foundation Trusts, and representatives from other hospitals and organisations, was opened by Phil Brice, director of governance and corporate development for the two trusts.
The morning was made up of a series of talks and presentations and gave those who attended a chance to find out about some of the research studies Somerset Partnership has supported and in which it has successfully participated.
One highlight was a talk from Sally-Anne Vincent, a research assistant from Oxford University, who spoke about Prevalence of Pathogenic Antibodies in Psychosis (PPiP2), a study which looks at the prevalence of pathogenic antibodies in people with symptoms of psychosis to which Somerset Partnership is currently recruiting.
Sally-Anne informed the audience that out of the Trusts taking part, not only was Somerset Partnership the first to successfully recruit an eligible patient, but that we were also managing to sign up more people than the other sites in our group.
There were also talks from Somerset Partnership staff, including a presentation from Corrine Birch, one of our physiotherapists, who spoke about her experience of taking part in research for the first time as a Principal Investigator on the GRASP study which looks at treating shoulder pain. Corrine said it had been a steep learning curve and recommended the experience to others.
Those present were also able to find out about upcoming research studies and events and how to get involved in research.
Andrew Harewood, head of research and clinical effectiveness at Somerset Partnership, said: “It was a really interesting and varied morning and it was great to provide the opportunity for colleagues to hear about some of the research we have taken part in.
“Research is a vital part of the work that we do to help our understanding of conditions, diseases, treatments and to help make sure that we are providing the best possible outcomes for our colleagues and our patients. Thank you to everyone who came along and took part.”